Aprea Therapeutics Inc (APRE) Quote

APRE 10Q due March 14

https://twitter.com/health_stocks/status/1767166092839989696

Thanks, do you have a link?

Analysts giving this a price target of $20.


Yes $20.


Let that sink in.

Dropping like a waterfall.

APRE is climbing, it climbed today in spite of a sale off going on. Holding should increase your PPS
IMO

Price target set for $3 buy and hold rating from last week
https://www.marketbeat.com/stocks/NASDAQ/APRE/

GM APRE time to work

GM APRE time to work

High volume today 43x avg

$APRE PT $3 can we see $2.40 today / Monday?

$APRE PT $3 can we see $2.40 today / Monday?

Hot Day for $APRE
insider buying and 40x average volume today so far

Aprea Therapeutics shares are trading higher after Wedbush initiated coverage on the stock with an Outperform rating and announced a $3 price target

Very strong!

Why? Any insider good news?

I’m joining in

coming off 53w low 1.46 just on thursday

https://ih.advfn.com/stock-market/NASDAQ/aprea-therapeutics-APRE/historical

$APRE 8 Catalyst on the way not including the potential buyout here. CEO Chris Schlade has sold his last 3 companies to BIG PHARMA. A lot of trials on going that have had "KNOCK YOUR SOCKS OFF RESULTS" Come see us on ST for more information and great DD.

Aprea Therapeutics, Inc. (NASDAQ: APRE): Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies (Monday, Sept. 20, at 11:35-11:40 am)

On heavy watch for Monday.

If the Monday data can be very promising, this will blow up.

This could get some nice legs over 6+, next week could be very interesting..

Good luck to all! Looks very promising!

Something special going on here with the gap n trap shake and bake BS.
institutions playing big time.

CASH ON HAND $77 MILLION
This company is sitting on $77 million in raised capital for research and trials. As noted in previous emails they have several trials ongoing, the most recent one was a success, and more to look forward to with that one in 2nd half of 2021.

Overview

We are a clinical-stage biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant p53 tumor suppressor protein. p53 is the protein expressed from the TP53 gene, the most commonly mutated gene in cancer. We believe that mutant p53 is an attractive therapeutic target due to the high incidence of p53 mutations across a range of cancer types and its involvement in key cellular activities such as apoptosis. Cancer patients with mutant p53 face a significantly inferior prognosis even when treated with the current standard of care, and a large unmet need for these patients remains.

Our lead product candidate, APR-246, or eprenetapopt, is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes, or MDS, and acute myeloid leukemia, or AML. Eprenetapopt has received orphan drug, fast track and breakthrough therapy designations from the FDA for MDS, orphan drug and fast track designations from the FDA for AML and orphan drug designation from the European Commission for MDS and AML, and we believe eprenetapopt will be a first-in-class therapy if approved by applicable regulators.

We are conducting, supporting and planning multiple clinical trials of eprenetapopt and APR-548:


--- Phase 3 Frontline MDS Trial -- In June 2020, we completed full enrollment of 154 patients in a pivotal Phase 3 trial of eprenetapopt with azacitidine for frontline treatment of TP53 mutant MDS. The pivotal Phase 3 trial is supported by data from two Phase 1b/2 investigator-initiated trials, one in the U.S. and one in France, testing eprenetapopt with azacitidine as frontline treatment in TP53 mutant MDS and AML patients. The data from the U.S. and French Phase 1b/2 trials were published in The Journal of Clinical Oncology in January 2021 and February 2021, respectively. In December 2020, we announced that our pivotal Phase 3 trial failed to meet its predefined primary endpoint of complete remission (CR) rate. Analysis of the primary endpoint at this data cut demonstrated a higher CR rate (53% more patients achieving a CR) in the experimental arm receiving eprenetapopt with azacitidine versus the control arm receiving azacitidine alone but did not reach statistical significance. Based on a thorough analysis of the current Phase 3 trial data and comparisons to the U.S. and French Phase 1b/2 trials, we believe that despite similar types and frequency of adverse events observed in the Phase 3 experimental arm and the Phase 1b/2 trials, patients in the Phase 3 experimental arm experienced substantially more study treatment dose modifications compared to the experience in the U.S. and French Phase 1b/2 trials. We believe that the dose modifications of eprenetapopt and azacitidine led to undertreatment in the Phase 3 experimental arm that negatively impacted efficacy, particularly the primary endpoint of CR rate. We continue to follow patients who remain on-study and anticipate discussing with FDA the Phase 3 data and future possible regulatory pathways in the second half of 2021.


--- Phase 2 MDS/AML Post-Transplant Trial -- We have completed enrollment of 33 patients in a single-arm, open-label Phase 2 trial evaluating eprenetapopt with azacitidine as post-transplant maintenance therapy in TP53 mutant MDS and AML patients who have received an allogeneic stem cell transplant. The primary endpoint of the trial is the rate of relapse-free survival (RFS) at 12 months, with a published benchmark of ~30%. An interim analysis in April 2021 showed a 62% rate of RFS at 12 months, with a median RFS of 462 days. An interim analysis of overall survival (OS) showed a 77% OS at 1 year, with a median number of events not yet reached. We anticipate initial results from the primary endpoint of RFS at 12 months in the second quarter of 2021.


---- Phase 1/2 AML Trial -- We are currently enrolling a Phase 1/2 clinical trial evaluating the safety, tolerability, and preliminary efficacy of eprenetapopt therapy in TP53 mutant AML patients. The lead-in portion of the trial evaluated the tolerability of eprenetapopt with venetoclax, with or without azacitidine, and no dose-limiting toxicities were observed in 12 patients receiving either regimen. Based on these results, we have expanded the trial to treat 33 additional frontline TP53 mutant AML patients with the combination of eprenetapopt, venetoclax and azacitidine. In the 19 frontline AML patients who are evaluable for efficacy with the triplet regimen, we have observed a 63% CR + CRi composite response rate and a 31% CR rate. We anticipate completion of enrollment in the triplet regimen expansion cohort during the second quarter of 2021 and availability of preliminary response rate data from the cohort also in the second quarter of 2021.


--- Phase 1 NHL Trial -- We are currently enrolling a Phase 1 clinical trial in relapsed/refractory TP53 mutant chronic lymphoid leukemia (CLL) assessing eprenetapopt with venetoclax and rituximab and eprenetapopt with ibrutinib in order to further assess eprenetapopt in hematological malignancies. The first patient was enrolled in the first quarter of 2021. We are also planning to evaluate the combination of eprenetapopt with venetoclax in relapsed/refractory mantle cell lymphoma.


--- Phase 1/2 Solid Tumor Trial – We are currently enrolling a Phase 1/2 clinical trial in relapsed/refractory gastric, bladder and non-small cell lung cancers assessing eprenetapopt with anti-PD-1 therapy. The dose-escalation phase of the trial enrolled 6 patients with advanced solid tumors and no dose-limiting toxicities were observed. Based on these results, we are enrolling expansion cohorts for patients with advanced gastric, bladder and non-small cell lung cancers and have currently enrolled 15 patients across these expansion arms. A poster presentation for this trial has been accepted for presentation at the 2021 ASCO Annual Meeting (abstract TPS3161).


--- APR-548 Phase 1 Trial – Our second product candidate, APR-548, is a next generation p53 reactivator that is being developed in an oral dosage form. We have planned a Phase 1 dose-escalation clinical trial evaluating safety, tolerability, and preliminary efficacy of APR-548 with azacitidine in frontline and relapsed/refractory MDS patients. We anticipate the first patient to be enrolled in the second quarter of 2021.

I know this isn't a NASDAQ message board. But some would have to feel that this could produce some good returns yet in CY 2021. Article today talked about how Aprea could have significant volatility approaching, signaling that a major move could be coming one way or the other. I think we know which way it would go with the news from 6/16/21.

Totally agree, I have been loading up at these prices. This was a $30 stock pre-failure of the last trial back in December 20. With yesterday's news of trial success for a different disease, I think we could move back to those levels in 2nd half of 2021.

Pump and dump pos imo??

sold some APRE on the pop today.

loaded shares of apre today. Seems to be corelated with the $rut.

Got my order in at $20+.

APRE is extemely undervalued chart shows the significant upside. With 10M float no brainer.



https://schrts.co/RWyDbWtr

ready to fill that huge gap.
Dont miss it ladies and gents.
Strong buy here.

I agree. This stock is demanding attention and it will get it. People are recognizing this as being oversold and there is a new round of stimulus checks being pumped into the economy. The wash sale rules are getting close and the institutions will have to put the money somewhere. This is a institutional play. They are heavy into this company and the cash reserves are in place. This appears to be a no brainer. I am pretty confident that we will be making a good return.

I'm in @ 5.69 looks good from here

APRE Chart and indicators looks ready for a huge upside move in the next days. Buying a starter position and watching closely.

Jan 28th marks the end of the waiting period for institutional wash sale. I think that $APRE is going to be reentered into many of their mutual funds. The opportunity to purchase shares at low entry is closing. I believe the momentum is growing and that there will be a significant upside swing.

Jan 28th marks the end of the waiting period for institutional wash sale. I think that $APRE is going to be reentered into many of their mutual funds. The opportunity to purchase shares at low entry is closing. I believe the momentum is growing and that there will be a significant upside swing.

Another buying opportunity has appeared. Looking forward to some positive news on these trials. The convention went well in my opinion. I was impressed by the conservation of the companies cash position. Also by placing a higher amount of people in the study may result in a better understanding of what works and doesn't.

Welcome! There is alot of information on the company's website. The idea of holding for a year seems really smart. Your bound to have some positive returns in such a long timeframe. They are financially sound and seem to be efficient in the daily operations and monitoring the cash burn rate. It seems like an oversold position that will spike with some positive news. There is institutional interest and positions. I am excited to see this in a years time. I feel like there will be many others to join the ride along the way. Again. Welcome, and I am looking forward to seeing more posts from you and others. Good luck to us all!

Hello just found this company on another bio board VS@M. Looks like a lot to offer over the next year. I will try and hear results of conference. Any new info here is appreciated

After a great premarket open the profit takers have showed up and destroyed the gains from opening. I expect that with those gains they will be back for more. My guess is a nice move up by the end of the day.

It's good to know they are still a staff of 17 employees. They will have enough cash on hand to last to 2023. I am sure there will be some momentum with their research by then. This is getting some good news. Looking forward to more.

A higher price at closing charts some positive momentum. The after hours continued the trend. Hopefully this stock will begin to grow at higher levels and a new higher resistance base is formed. Fingers and toes crossed. This is the bottom.

I am hoping with the conference tomorrow that it will bring some attention to the institutional investors. It has potential to move up this week and I for one have my fingers crossed that they see this as an opportunity to buy more shares. Good luck!!

Premarket is up. I hope it will continue throughout the day

Yeah. I agree. This one attempt has allowed us to get a good price on a up and coming stock. Remember to buy on the news and sell some before the results.

Yes--I think we are on the right track for sure with $APRE. Still lots here--way more than the one trial.